Ocular Therapeutix, Inc. (OCUL)
10.78
-0.30
(-2.66%)
USD |
NASDAQ |
Aug 24, 16:00
10.78
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Gross Profit Margin (Quarterly) : 85.08% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.08% |
| March 31, 2026 | 87.68% |
| December 31, 2025 | 87.97% |
| September 30, 2025 | 87.80% |
| June 30, 2025 | 85.56% |
| March 31, 2025 | 88.20% |
| December 31, 2024 | 92.80% |
| September 30, 2024 | 89.88% |
| June 30, 2024 | 90.82% |
| March 31, 2024 | 91.02% |
| December 31, 2023 | 90.64% |
| September 30, 2023 | 90.87% |
| June 30, 2023 | 91.41% |
| March 31, 2023 | 90.92% |
| December 31, 2022 | 92.80% |
| September 30, 2022 | 91.03% |
| June 30, 2022 | 90.58% |
| March 31, 2022 | 90.14% |
| December 31, 2021 | 91.01% |
| September 30, 2021 | 89.22% |
| June 30, 2021 | 90.65% |
| March 31, 2021 | 87.85% |
| December 31, 2020 | 90.75% |
| September 30, 2020 | 81.02% |
| June 30, 2020 | 46.40% |
| Date | Value |
|---|---|
| March 31, 2020 | 68.61% |
| December 31, 2019 | 47.87% |
| September 30, 2019 | 2.77% |
| June 30, 2019 | -98.92% |
| March 31, 2019 | -83.74% |
| December 31, 2018 | -38.69% |
| September 30, 2018 | -38.15% |
| June 30, 2018 | -10.96% |
| March 31, 2018 | -89.71% |
| December 31, 2017 | -31.62% |
| September 30, 2017 | -16.06% |
| June 30, 2017 | -4.57% |
| March 31, 2017 | 20.84% |
| December 31, 2016 | 50.39% |
| September 30, 2016 | 53.88% |
| June 30, 2016 | 29.25% |
| March 31, 2016 | 48.54% |
| December 31, 2015 | 33.03% |
| September 30, 2015 | 48.65% |
| June 30, 2015 | 41.83% |
| March 31, 2015 | 46.24% |
| December 31, 2014 | 61.58% |
| September 30, 2014 | 77.62% |
| June 30, 2014 | -76.29% |
| March 31, 2014 | -277.8% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| EyePoint, Inc. | -36.09% |
| LENZ Therapeutics, Inc. | 94.90% |
| Merck & Co., Inc. | 71.51% |
| Theravance Biopharma, Inc. | 93.04% |
| ANI Pharmaceuticals, Inc. | 54.97% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -64.97% |
| Return on Assets | -48.98% |
| Return on Invested Capital | -55.62% |
| Profit Margin (Quarterly) | -584.5% |
| Operating Margin (Quarterly) | -609.3% |
| Return on Net Operating Assets | -543.7% |